Is TPST stock a buy after H.C. Wainwright sets a $51 price target?

Tempest Therapeutics (NASDAQ:TPST) is gaining momentum this week after H.C Wainwright listed a $51 price target on the stock. The stock is running strong after the completion of the Millendo Therapeutics merger. TPST has gained 108% over the past week of trading, which is driving large amounts of interest in the stock. Tempest is a clinical-stage oncology company that is developing small molecule therapeutics to treat cancer. They aim to do this through mechanisms that directly kill tumor cells and activate tumor-specific immunity.

What is Wallstreet saying about TPST stock?

Firstly, 2 Wallstreet analysts have covered TPST stock, with the average price target currently sits at $37 a share. The average target represents an impressive upside of 64% considering its recent performance. Here are the following targets:

H.C. Wainwright sets street high price target to $51

On July 13th, H.C. Wainwright analyst Joseph Pantginis initiated coverage on Tempest Therapeutics with a price target of $51 a share. The analyst noted a strategic portfolio of targeted therapies in oncology “gives Tempest an edge”. In addition the analyst added that Tempest sets itself apart from other companies in the immuno-oncology space by shifting its focus to innovative targets and mechanisms according to The Business Insider.

Piper Sandler set target to $23 a share

Piper Sandler analyst Edward Tenthoff covered TPST stock with an Overweight rating and $23 price target. It is worth noting the stock was trading at $10.93 at the time the target was released. The analyst told investors Tempest Therapeutics has a unique pipeline and experienced management team according to theFly.

Is TPST stock a buy after H.C. Wainwright sets a $51 price target?

What’s in the pipeline for Tempest Therapeutics TPST

Tempest Therapeutics currently has three therapies in the pipeline. These are the TPST-1495 (DUAL EP2/EP4 ANTAGONIST), TPST-1120 (PPARα ANTAGONIST) and TREX-1 (INHIBITOR). To simplify this, TPST-1495 and TPST-1120 are in Phase 1 studies which are designed to study both agents as monotherapies and in combination with other approved agents to treat a wide range of tumours. However, the TREX-1 is designed to activate selectively the cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity. See the full pipeline here.

“With our novel programs, including TPST-1495 and TPST-1120 progressing in the clinic, access to the public markets was of strategic importance as we look forward to a number of potential catalysts in the future and advance towards our goal to offer patients with cancer meaningful therapeutic options.” said Steve Brady, chief executive officer of Tempest

Written by Tyger Fitzpatrick, Founder of Youth Investment Group.

The information above is not financial advice. Youth Investment Group has no liability for personal financial interests or investment decisions. You should make your own investment decisions based upon your own research and what you believe is best for you.

Subscribe to our Youtube channel here.

We are now official partners with eToro. If you are interested in joining eToro click the link here or the banner below. Please see the disclaimer below regarding use of Etoro. Furthermore, for more information on our partnerships, see our disclosure statement here.

eToro Disclaimer – Your capital is at risk 

eToro is a multi-asset platform which offers both investing in stocks and cryptoassets, as well as trading CFD assets. Please note that CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money. 

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.